Clinical Trial Update: Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis [Phase 1]

View source ↗

Summary

Phase I study of recombinant human interleukin-10 (SCH 52000) in patients with granulomatosis with polyangiitis (Wegener's granulomatosis) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Vasculitis

Drugs mentioned

• Recombinant human interleukin-10 (SCH 52000) (interleukin-10)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Vasculitis, Wegener's Granulomatosis | Phase 1 | Status: COMPLETED